Vaping may raise cancer and heart disease risk, study suggests

Vaping may raise the risk of certain cancers and heart disease, according to a team of scientists who studied the effects of e-cigarette smoke on healthy mice and human cells.

Researchers found evidence that nicotine inhaled from e-cigarettes could be converted into chemicals that damage DNA in the heart, lungs and bladder, and dampen down the body’s genetic repair mechanisms.

Moon-shong Tang, professor of environmental medicine at New York University, said the DNA changes were similar to those linked to secondhand smoke, but added that more work was needed to see whether vaping really did increase cancer rates.

The researchers have now launched long-term experiments to look at the development of tumours in mice exposed to vapour from e-cigarettes, but Tang does not expect to have answers any time soon. “The results may take years to come in because cancer is such a slow process,” he said.

While some researchers said the work was important, others all but dismissed it as irrelevant to humans. The mice were exposed to high levels of e-cigarette smoke and the effects may be very different in people who inhale nicotine from vaping, critics caution.

“This study shows nothing at all about the dangers of vaping,” said Peter Hajek, director of the Tobacco Dependence Research Unit at Queen Mary University of London. “It doesn’t show that vaping causes cancer.”

“This is one in a long line of false alarms which may be putting people off the switch from smoking to vaping which would undoubtedly be of great benefit to them,” he added. “The best current estimate is that vaping poses, at worst, some 5% of risks of smoking.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The